Risks To Shareholder Returns Are Elevated At These Prices For Arcellx, Inc. (NASDAQ:ACLX)

Simply Wall St.2024-12-20

Arcellx, Inc.'s (NASDAQ:ACLX) price-to-sales (or "P/S") ratio of 26.1x might make it look like a strong sell right now compared to the Biotechs industry in the United States, where around half of the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493420789?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2024-12-20 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493420789","market":"us","top_or_hot":-1,"title":"Risks To Shareholder Returns Are Elevated At These Prices For Arcellx, Inc. (NASDAQ:ACLX)","media":"Simply Wall St.","content":"<div>\n<p>Arcellx, Inc.'s (NASDAQ:ACLX) price-to-sales (or \"P/S\") ratio of 26.1x might make it look like a strong sell right now compared to the Biotechs industry in the United States, where around half of the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/risks-to-shareholder-returns-are-elevated-at-these-prices-fo-433\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Risks To Shareholder Returns Are Elevated At These Prices For Arcellx, Inc. (NASDAQ:ACLX)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRisks To Shareholder Returns Are Elevated At These Prices For Arcellx, Inc. (NASDAQ:ACLX)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/risks-to-shareholder-returns-are-elevated-at-these-prices-fo-433><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arcellx, Inc.'s (NASDAQ:ACLX) price-to-sales (or \"P/S\") ratio of 26.1x might make it look like a strong sell right now compared to the Biotechs industry in the United States, where around half of the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/risks-to-shareholder-returns-are-elevated-at-these-prices-fo-433\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/risks-to-shareholder-returns-are-elevated-at-these-prices-fo-433","article_id":"2493420789","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493420789","pubTimestamp":1734695133,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Arcellx, Inc.'s ( NASDAQ:ACLX ) price-to-sales (or \"P/S\") ratio of 26.1x might make it look like a strong sell right...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Arcellx,Inc.（纳斯达克股票代码：ACLX）的股东回报风险在这些价格下会增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACLX":1,".IXIC":1,"NDAQ":1,"USJW.SI":0.6,"USAW.SI":0.6,"TSYW.SI":0.6,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NVIW.SI":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Arcellx, Inc.'s (NASDAQ:ACLX) price-to-sales (or \"P/S\") ratio of 26.1x might make it look like a strong sell right now compared to the Biotechs industry in the United States, where around half of the companies have P/S ratios below 9.4x and even P/S below 3x are quite common.   Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so lofty.     See our latest analysis for Arcellx NasdaqGS:ACLX Price to Sales Ratio vs Industry December 20th 2024 What Does Arcellx's P/S Mean For Shareholders?  Arcellx could be doing better as it's been growing revenue less than most other companies lately.   Perhaps the market is expecting future revenue performance to undergo a reversal of fortunes, which has elevated the P/S ratio.  You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.      Keen to find out how analysts think Arcellx's future stacks up against the industry? In that case, our free report is a great place to start.  Do Revenue Forecasts Match The High P/S Ratio?   There's an inherent assumption that a company should far outperform the industry for P/S ratios like Arcellx's to be considered reasonable.   Retrospectively, the last year delivered an exceptional 230% gain to the company's top line.   However, the latest three year period hasn't been as great in aggregate as it didn't manage to provide any growth at all.  Accordingly, shareholders probably wouldn't have been overly satisfied with the unstable medium-term growth rates.     Looking ahead now, revenue is anticipated to climb by 12% each year during the coming three years according to the analysts following the company.  With the industry predicted to deliver 114% growth per year, the company is positioned for a weaker revenue result.  With this in consideration, we believe it doesn't make sense that Arcellx's P/S is outpacing its industry peers.  It seems most investors are hoping for a turnaround in the company's business prospects, but the analyst cohort is not so confident this will happen.  There's a good chance these shareholders are setting themselves up for future disappointment if the P/S falls to levels more in line with the growth outlook.    The Final Word  Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.  It comes as a surprise to see Arcellx trade at such a high P/S given the revenue forecasts look less than stellar.  Right now we aren't comfortable with the high P/S as the predicted future revenues aren't likely to support such positive sentiment for long.  This places shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.      It is also worth noting that we have found 3 warning signs for Arcellx (1 can't be ignored!) that you need to take into consideration.   If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios. New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493420789"}